These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 37615532)
1. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report. He X; Hou L; Bai J; Sun C; Wang D; An G Anticancer Drugs; 2024 Jan; 35(1):101-108. PubMed ID: 37615532 [TBL] [Abstract][Full Text] [Related]
2. 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer. Shiraishi A; Oh-Hara T; Takahashi Y; Uchibori K; Nishio M; Katayama R Biochem Biophys Res Commun; 2024 Sep; 725():150255. PubMed ID: 38897043 [TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. Iwama E; Zenke Y; Sugawara S; Daga H; Morise M; Yanagitani N; Sakamoto T; Murakami H; Kishimoto J; Matsumoto S; Nakanishi Y; Goto K; Okamoto I Eur J Cancer; 2022 Feb; 162():99-106. PubMed ID: 34959152 [TBL] [Abstract][Full Text] [Related]
5. Metastatic Yun KM; Bazhenova L BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567 [TBL] [Abstract][Full Text] [Related]
6. FDA Gives Nod to T-DXd for HER2-Mutant NSCLC. Cancer Discov; 2022 Oct; 12(10):2224. PubMed ID: 35984233 [TBL] [Abstract][Full Text] [Related]
7. Clinical and Genomic Features of Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473 [TBL] [Abstract][Full Text] [Related]
8. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. Perez J; Garrigós L; Gion M; Jänne PA; Shitara K; Siena S; Cortés J Expert Opin Biol Ther; 2021 Jul; 21(7):811-824. PubMed ID: 33759669 [TBL] [Abstract][Full Text] [Related]
9. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors. Indini A; Rijavec E; Grossi F Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310 [TBL] [Abstract][Full Text] [Related]
10. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514 [TBL] [Abstract][Full Text] [Related]
11. Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring Kato Y; Kato Y; Minegishi Y; Suzuki T; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Kubota K; Terasaki Y; Seike M; Gemma A Onco Targets Ther; 2021; 14():5315-5319. PubMed ID: 34848974 [TBL] [Abstract][Full Text] [Related]
12. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet. Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002 [TBL] [Abstract][Full Text] [Related]
13. Trastuzumab Deruxtecan in Patients With Goto K; Goto Y; Kubo T; Ninomiya K; Kim SW; Planchard D; Ahn MJ; Smit EF; de Langen AJ; Pérol M; Pons-Tostivint E; Novello S; Hayashi H; Shimizu J; Kim DW; Kuo CH; Yang JC; Pereira K; Cheng FC; Taguchi A; Cheng Y; Feng W; Tsuchihashi Z; Jänne PA J Clin Oncol; 2023 Nov; 41(31):4852-4863. PubMed ID: 37694347 [TBL] [Abstract][Full Text] [Related]
14. [Treatment of Non-Small Cell Lung Cancer with HER2 Alterations]. Takakura T; Yamamoto N Gan To Kagaku Ryoho; 2023 Jul; 50(7):768-772. PubMed ID: 37496218 [TBL] [Abstract][Full Text] [Related]
15. Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC. Cancer Discov; 2021 Dec; 11(12):OF3. PubMed ID: 34675060 [TBL] [Abstract][Full Text] [Related]
16. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective. Aoki M; Iwasa S; Boku N Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464 [TBL] [Abstract][Full Text] [Related]